18:36:24 EDT Tue 23 May 2017
Enter Symbol
or Name
USA
CA



Z:SNY - SANOFI - http://www.sanofi-aventis.com18:36:24 EDT
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SNY - Z0.146.00 · 49.200.649.07-0.09-0.21,835.686,5847,33149.3399  49.41  48.99550.24  36.8116:15:31May 2215 min RT 2¢

Recent Trades - Last 10 of 7331
Time ETExPriceChangeVolume
16:15:31Z49.07-0.09132
16:02:05Z49.07-0.09198
16:02:03Z49.07-0.092,426
16:02:01Z49.07-0.0916,817
15:59:57Z49.08-0.0814
15:59:55Z49.085-0.075100
15:59:55Z49.08-0.08165
15:59:52Z49.08-0.08100
15:59:52Z49.09-0.07100
15:59:50Z49.08-0.08100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2017-05-22 17:47U:SNYNews ReleaseSanofi and Regeneron Announce FDA Approval of Kevzara ® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients
2017-05-22 17:45U:SNYNews ReleaseRegeneron and Sanofi Announce FDA Approval of Kevzara ® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients
2017-05-11 08:30U:SNYNews ReleaseAllegra ® Allergy Gears Up for Bike to Work Day Across the U.S.
2017-05-02 08:30U:SNYNews ReleaseSurvey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment
2017-04-28 07:30U:SNYNews ReleaseSanofi Delivers Robust Q1 2017 Financial Results
2017-04-28 01:00U:SNYNews ReleaseRegeneron and Sanofi Announce Kevzara ® (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA